Aug 29, 2015 by Michael Douglass3 Reasons to Avoid Dyax Corp. StockInterested in Dyax? Here are three reasons to think about staying away.
Aug 24, 2015 by Michael DouglassWhy I Just Bought This Big Dividend StockStag Industrial is a cool mix of income and growth, and I'm pleased to add some more to my portfolio.
Aug 15, 2015 by Michael Douglass3 Numbers Show Why Gilead Sciences Inc. Is in a Great Position Today3 impressive numbers, one huge growth story.
Aug 15, 2015 by Michael Douglass3 Reasons Why I Just Bought Biogen Inc. StockI think negative headlines have missed Biogen's true opportunities.
Jul 30, 2015 by Michael Douglass4 Key Updates We Just Heard from Dyax Corp.Dyax's Q2 earnings call provided a wealth of new knowledge for investors -- and here are the high points.
Jul 25, 2015 by Michael DouglassMost Americans Just Guess Their Retirement Number -- Here's How You Can Do BetterWant to retire well? Have a plan.
Jul 25, 2015 by Michael DouglassAnthem's Government Healthcare Strategy Is Surprisingly BrilliantIt could end up benefiting them in a surprising way.
Jul 24, 2015 by Michael Douglass3 Questions Dyax Needs to Answer on WednesdayEarnings incoming: Here are the three questions management should answer on the earnings call.
Jul 13, 2015 by Michael Douglass3 Ways Rite Aid Is Driving Sales GrowthRead below for three ways the underdog retail pharmacy is fighting to grow and retain market share in the U.S.
Jun 30, 2015 by Michael DouglassThe Overlooked Reason Why I Think Gilead Sciences Stock Remains UndervaluedEven after an incredible multi-year run, I think Gilead Sciences still has a lot of room to run. And surprisingly, it's got nothing to do with the P/E ratio.
Jun 30, 2015 by Michael DouglassThe Overlooked Reason Why I Think Gilead Sciences Stock Remains UndervaluedEven after an incredible multi-year run, I think Gilead Sciences still has a lot of room to run. And surprisingly, it's got nothing to do with the P/E ratio.
Jun 30, 2015 by Michael DouglassIs It Time to Buy Dyax Corp. Stock?Dyax is an intriguing company that could make patients' lives a lot better. But is it worth buying at this price?
Jun 30, 2015 by Michael Douglass3 Ways Rite Aid Is Transforming Before Our Very EyesAmerican healthcare is changing, and Rite Aid must change with it. Here are three ways the company is adapting, and a hint of the exciting opportunities those developments can provide for investors.
Jun 28, 2015 by Michael DouglassHere's the Typical American's Retirement Readiness. How Do You Compare?Read on to learn how prepared Americans are for retirement, and what you can do to get ready.
Dec 13, 2014 by Michael Douglass and John MaxfieldIt's Not Always a Good Idea to Follow Warren BuffettWhat's right for Berkshire Hathaway isn't necessarily right for individual investors.
Oct 15, 2014 by Michael Douglass and Alison SouthwickJohnson & Johnson Earnings: Showing Surprising WeaknessJohnson & Johnson's strong earnings masked some surprising weaknesses. Watch below to find out more.
Aug 12, 2014 by Michael DouglassWhy Dendreon Corporation Stock Slumped TodayDendreon's 10-Q is causing investors some serious heartburn.
Jul 24, 2014 by Michael Douglass and Dave WilliamsonWhy Gilead Sciences, inc. Stock Was Flat TodayBut Gilead Sciences turned in a great quarter. Here's why.
Jul 24, 2014 by Michael Douglass and Dave WilliamsonWhy Celgene Stock Was Down 3% TodayWhat's not to love about Celgene earnings?
Jul 24, 2014 by Michael Douglass and Dave WilliamsonWere There Any Silver Linings in GlaxoSmithKline Stock's Earnings Failure?It was a rough quarter for GlaxoSmithKline. Were there any silver linings?
